AMENDMENTS TO THE CLAIMS:

- 1. (original) A structurally biased integrin I domain protein comprising an amino acid sequence that is less than about 98% identical to human integrin I domain protein wherein the alterations to the protein occur in at least two noncontiguous regions wherein said integrin I domain protein is artificially biased to exist in an "open" conformation.
- 2. (original) A full length integrin comprising the domain of claim 1.
- 3. (original) A non-naturally occurring integrin I domain protein comprising at least 3 amino acid substitutions as compared to human integrin I domain protein, wherein at least 2 of said substitutions are selected from the amino acid residues at positions selected from positions 139, 153,156, 157, 160, 199, 215, 219, 223, 238, 239, 240, 259, 269, 271, 287, 299, 308.
- 4. (original) The non-naturally occurring integrin I domain protein according to claim 3 comprising substitutions at positions 156, 160, 199, 215, 238, 239, 240, 259, 269, 271, 287, 299, 308.
- 5. (original) The non-naturally occurring integrin I domain protein according to claim 3 comprising substitutions at positions 156, 199, 215, 238, 239, 240, 259, 287, 299.
- 6. (original) The non-naturally occurring integrin I domain protein according to claim 3 comprising substitutions at positions 139, 153, 157, 199, 238, 239, 287, 299.

7. (original) The non-naturally occurring integrin I domain protein according to claim			
3 comprising substitutions at positions 215, 219, 223, 238.			
8. (Cancelled)			
9. (Cancelled)			
10. (Cancelled)			
To: (Cancelled)			
11. (Cancelled)			
Tr. (Canonica)			
12. (Cancelled)			
13. (Cancelled)			
13. (Canocitea)			
14. (original) A pharmaceutical composition comprising an integrin I domain protein			
according to claim 1, 2, or 3 and a pharmaceutical carrier.			
according to claim 1, 2, or 3 and a pharmaceutical carrier.			
15. (Cancelled)			
13. (Cancened)			
16. (Cancelled)			
10. (Cancened)			
17. (Cancelled)			
17. (Cancelled)			
1110151_1.DOC 3			

18.	Cancelled)		
19.	Cancelled)		
20.	Cancelled)		
21.	Cancelled)		
22.	Cancelled)		
23.	Cancelled)		
24.	Cancelled)		
25.	Cancelled)		
26.	Cancelled)		
27.	Cancelled)		
28.	Cancelled)		
29.	Currently Amended) A composition comprising an integrin that is artificiall	у	
biased to exist in the open conformation, where the artificial bias is a result of			

noncontiguous alterations of the protein, these alterations resulting in a protein that is less than 98% identical to the wild-type protein, erystalized crystallized with ligand.

- 30. (Currently Amended) A composition comprising an integrin that is artificially biased to exist in the closed conformation, where the artificial bias is a result of noncontiguous alterations of the protein, these alterations resulting in a protein that is less than 98% identical to the wild-type protein, erystalized crystallized with ligand.
- 31. (New) A non-naturally occurring integrin I domain protein having SEQ ID NO:5.
- 32. (New) A non-naturally occurring integrin I domain protein having SEQ ID NO:4.
- 33. (New) A non-naturally occurring integrin I domain protein having SEQ ID NO:3.